The collaboration will focus on the discovery and development of novel AAV capsids for CNS diseases.
As a part of the collaboration, Prevail will receive rights to utilize one of Lacerta's novel AAV capsids for select undisclosed CNS targets.
In addition, Lacerta's proprietary AAV capsid platform will be utilized to discover and develop novel AAV capsids that are optimized to target desired CNS tissues and cell types.
The collaboration will leverage Lacerta's established expertise in AAV technologies and Prevail's development and clinical capabilities, with the goal of accelerating development of gene therapies for patients with neurodegenerative disorders.
Lacerta will lead capsid discovery, screening, and validation, while Prevail will complete preclinical and Investigational New Drug-enabling studies with therapeutic payloads.
Prevail will be responsible for all manufacturing, clinical development, and commercialization.
Under the terms of the agreement, Lacerta will receive an upfront payment and will be eligible for development and commercial milestones, as well as tiered royalties on future net sales of products that incorporate capsids covered under the collaboration.
Lilly will also provide Lacerta with new financing under the terms of a convertible promissory note agreement.
Lacerta Therapeutics is a fully-integrated gene therapy company that is focused on leveraging its proprietary capsid technology and scalable manufacturing platforms to advance adeno-associated virus based therapies via three primary approaches: gene replacement, gene modulation and novel vectorization of antibodies.
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials